Baird Maintains a 'Neutral' on Acorda Therapeutics (ACOR); Zanaflex Could Soon See Generic Competition, But DCF Impact Is Limited
Tweet Send to a Friend
Baird maintains a 'Neutral' on Acorda Therapeutics, Inc. (NASDAQ: ACOR), price target of $31.
Baird analyst says, "No change to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "No change to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
